Slide 1: Corporate Presentation August 2026
hed August 2026 es . % 0% 7 © Oe overs: nent ssf a) de 2 hg > bs es etatatns eee ©~Next@ure eetctetctete os.” Corporate Presentation oO e e@ e NASDAQ: NXTC
Slide 2: Forward-Looking Statements
Next@ure | 2 Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts, they may be deemed to be forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements are based on current expecta
Slide 3: ADC Pipeline Progress
NextGure | 3 ADC Pipeline Progress PROGRAMS TARGET PAYLOAD PRECLINICAL PHASE 1 PHASE 2 Asimeere Uterine Serous Carcinoma (USC) LNCB74 Excusive icense to B7-H4 MMAE Breast, Ovarian, §LCB Endometrial , ACC-1 ekg
Slide 4: SIM0505 is a Differentiated CDH6 TOPOi ADC
Next@ure SIMO505 is a Differentiated CDH6 TOPOi ADC VALIDATED TARGET WITH PROPRIETARY TOPOi PAYLOAD CDH6 mAb Linker Payload CPT116 (TOPO) DAR 8.0 Cysteine conjugation R° WY ») GGFG Linker -- ») R! Unique Binding Epitope Gly-Gly-Phe-Gly Provides High Systemic Clearance sen oneal det is. with Increase
Slide 5: SIM0505 Structural and Functional Differentiation by Design
Next@ure | 5 SIMO505 Structural and Functional Differentiation by Design * Unique distal EC1 epitope on CDH6 * Ovarian, uterine, RCC, NSCLC * High affinity & internalization * PK proportionality Ec1 o. Ec2 SIMO505 Membrane * Designed for better tolerability & safety ¢Hydrophilic & high systemic clea
Slide 6: SIM0505 Development Plan
SIMO505 Development Plan Next@ure | s COMPLETED INITIATED PLANNING DOSE ESCALATION ——— _ DOSE OPTIMIZATION — ene prilenimen PIVOTAL TRIAL Ovarian, USC, RCC, EC PROC & USC PROC Dose Intermediate Escalation Doses SIMO0S505 n= 215) n= 215) | *Generating recommended *ORR (RECIST 1.1) pivotal trial dose
Slide 7: SIM0505 Patient Demographics
SIM0505 Patient Demographics Next@ure Baseline US Patients China Patients All Patients Characteristic (n = 25) (n = 34) (n= 59) Age, years Median (range) 63 (49-78) 56 (42-72) 58 (42-78) Sanath) Patient Population Male 0 (0.0) 2(5.9) 2 (3.4) eae 25 (100) 32 (94.1) 57 (96.6) * Poor performance status
Slide 8: SIM0505 Has Shown a Well Manageable Safety Profile
NextGure | s SIM0505 Has Shown a Well Manageable Safety Profile 1.6 - 9.6 mg/kg Overview of Adverse Events (n=59) n(%) Treatment-emergent adverse events (TEAEs) (%) 59 (100) Grade >3 32 (54.2) _ Grade 5 * 2 (3.4) TEAEs related to study drug (TRAEs) (%) 57 (96.6) Grade >3 28 (47.5) | Grade 5 te} Any
Slide 9: Most Common TEAEs (≥10%)
Most Common TEAEs (210%) Next@ure Anemia Platelet count decreased Vomiting Neutrophil count decreased White blood cell count decreased Nausea Hypokalaemia Hyponatraemia Aspartate aminotransferase increased Fatigue 288 Decreased appetite 288 Constipation 254 Alanine aminotransferase increased 237 Hyp
Slide 10: Swimmer Plot All Patients at All Doses
Swimmer Plot All Patients at All Doses Next@ure wgsoc-12R 3 H@SOC- 3R R 201005 5201006 320700 5205008 - 5201008 - 203001 5201002 ‘3103004 - HGSOC- aR 5206001 - HGSOC- 38 5203008 - HGSOC- 38 Dose Levels Hy 1.6 me/kg Gh 3.2 me/kg Hl 4.8 mg/kg 1 5.6 mg/kg BB 6.4 me/kg Wl 7.2 me/kg Hl 8.0 me/kg 9.6 mg/k
Slide 11: Ovarian Cancer at Therapeutic Doses (4.8 – 8.0 mg/kg)
Ovarian Cancer at Therapeutics Doses (4.8 — 8.0 mg/kg) NextGure | 1 s20soo -nesoc-9a —t 5205003-Hasoc-6a —| s208002-nasoc-sa —t $105001, 202001 $104007 204001 5202002 s105001 5208005 -HGsOC- 28 8204004 - HGsOC - 28 206002 - HGSOC - 28 5207001 -HasOC - 48 5205004-HGEOC-5R s20100¢-Hasoc - 68 5206005 -
Slide 12: Ovarian Cancer (4.8 – 8.0 mg/kg)
Ovarian Cancer (4.8 -— 8.0 mg/kg) NextGure | 12 Tumor Percent Change from Baseline 30 15 ° 4 a @ t) -60 -75 5103008 / HGSOC / SR 5208001 / HGSOC-FT / 3k s201002 / HGEOC / aR 5203008 / HGSOC / 4k 5108007 / HGSOC / 4k 5102009 / HGSOC / SR 5101009 / LGSOC / 3k 5104006 / HGSOC / 10R 5103003 / HGSOC / 3k
Slide 13: Ovarian Cancer (4.8 – 8.0 mg/kg)
Ovarian Cancer (4.8 - 8.0 mg/kg) NextGure | 13 wos rae Tumor Percent Change from Baseline Cs os ak Peo F & me FS t F on Dose Levels wm 48 mg/kg B56 mg/kg 64 mg/kg Hl 8.0 mg/kg Weeks on Treatment Data cut O7Apr26 * Most patients (15/17) had tumor shrinkage * Increasing tumor shrinkage with continued
Slide 14: Uterine Serous Carcinoma (4.8 – 8.0 mg/kg)
Uterine Serous Carcinoma (4.8 -— 8.0 mg/kg) Next@ure 5201001 5205006 5206003 5201005 5201006 5203001 USC -1R USC -2R USC -3R USC. 2R USC -3R USC -aR Dose Levels HB 6.4 mg/kg Hl 7.2 me/ke Hl 8.0 mg/kg T T T T T T T Weeks on Treatment * Rare and highly aggressive form of endometrial cancer * Rapid pro
Slide 15: Opportunity to Develop Differentiated CDH6 ADC Therapeutic
Gure | 15 Opportunity to Develop Differentiated CDH6 ADC Therapeutic CDH6 ADC
Slide 16: Programs Available for Partnering
Programs Available for Partnering NextGure | 16 PROGRAMS TARGET CELLS DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 Combo else: Matrix Colorectal (CRC) NC525 LAIR-1 em Acute Myeloid Leukemia NC605 $15 Osteoclasts [peemechnbbaed Imperfecta Neurons Disease